^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AGAR T cells
i
Other names: AGAR T cells, Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells, GPC3-CAR and the IL15 cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Baylor College of Medicine
Drug class:
IL-15R stimulant, GPC-3-targeted CAR-T immunotherapy
Related drugs:
18d
H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
Enrollment change
|
GPC3 (Glypican 3) • IL15 (Interleukin 15)
|
AGAR T cells
2ms
H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
Enrollment closed • Trial completion date
|
GPC3 (Glypican 3)
|
AGAR T cells
5ms
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (clinicaltrials.gov)
P1, N=27, Recruiting, Baylor College of Medicine | Trial completion date: Dec 2039 --> Dec 2040 | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
AGAR T cells
8ms
H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=24, Recruiting, Baylor College of Medicine | Trial primary completion date: Feb 2025 --> Oct 2025
Trial primary completion date
|
GPC3 (Glypican 3)
|
AGAR T cells
almost4years
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=27, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Jun 2021
Enrollment open • Trial initiation date
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • AGAR T cells
4years
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=27, Not yet recruiting, Baylor College of Medicine
Clinical • New P1 trial
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • AGAR T cells
over4years
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=24, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
GPC3 (Glypican 3)
|
GPC3 positive
|
fludarabine IV • AGAR T cells • cyclophosphamide intravenous
over4years
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2021 --> May 2021
Clinical • Trial initiation date
|
GPC3 (Glypican 3)
|
GPC3 positive
|
fludarabine IV • AGAR T cells • cyclophosphamide intravenous
Share via
